Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Papi

Showing results (291-300 of 430) with videos related to

Pageof 43
Sort By:
The Journal of Allergy and Clinical Immunology. in Practice|December 27, 2016
Identifying Risk of Future Asthma Attacks Using UK Medical Record Data: A Respiratory Effectiveness Group InitiativeJohn D Blakey, David B Price, Emilio Pizzichini, et al.
Allergy|August 17, 2021
From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseasesIan D Pavord, Elisabeth H Bel, Arnaud Bourdin, et al.
Allergy|July 11, 2023
Dupilumab sustains efficacy in patients with moderate-to-severe type 2 asthma regardless of inhaled corticosteroids doseIan D Pavord, Arnaud Bourdin, Alberto Papi, et al.
Annals of the American Thoracic Society|September 17, 2025
Prevalence and Clinical Characteristics of Persistent Airflow Limitation in the NOVELTY CohortRichard Beasley, Rod Hughes, Alvar Agusti, et al.
Journal of Inflammation (London, England)|November 21, 2023
SARS-CoV-2 infection as a model to study the effect of cinnamaldehyde as adjuvant therapy for viral pneumoniaBianca Vezzani, Mariasole Perrone, Marianna Carinci, et al.
Allergy|July 28, 2022
Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate-to-severe type 2 asthmaAlberto Papi, Jonathan Corren, Mario Castro, et al.
Respiratory Medicine|September 10, 2022
Dupilumab efficacy in subgroups of type 2 asthma with high-dose inhaled corticosteroids at baselineArnaud Bourdin, J Christian Virchow, Alberto Papi, et al.
The Journal of Allergy and Clinical Immunology. in Practice|December 26, 2022
Dupilumab Efficacy in Patients With Uncontrolled or Oral Corticosteroid-Dependent Allergic and Nonallergic AsthmaGuy Brusselle, Santiago Quirce, Alberto Papi, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|December 17, 2009
Oxidative/nitrosative stress selectively altered A(2B) adenosine receptors in chronic obstructive pulmonary diseaseKatia Varani, Gaetano Caramori, Fabrizio Vincenzi, et al.
American Journal of Respiratory and Critical Care Medicine|February 8, 2024
Biomarkers Associated with Lung Function Decline and Dupilumab Response in Patients with AsthmaIan D Pavord, Lucia De Prado Gómez, Guy Brusselle, et al.
Pageof 43

Showing results (291-300 of 430) with videos related to

Sort By:
Pageof 43
The Journal of Allergy and Clinical Immunology. in Practice|December 27, 2016
Identifying Risk of Future Asthma Attacks Using UK Medical Record Data: A Respiratory Effectiveness Group InitiativeJohn D Blakey, David B Price, Emilio Pizzichini, et al.
Allergy|August 17, 2021
From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseasesIan D Pavord, Elisabeth H Bel, Arnaud Bourdin, et al.
Allergy|July 11, 2023
Dupilumab sustains efficacy in patients with moderate-to-severe type 2 asthma regardless of inhaled corticosteroids doseIan D Pavord, Arnaud Bourdin, Alberto Papi, et al.
Annals of the American Thoracic Society|September 17, 2025
Prevalence and Clinical Characteristics of Persistent Airflow Limitation in the NOVELTY CohortRichard Beasley, Rod Hughes, Alvar Agusti, et al.
Journal of Inflammation (London, England)|November 21, 2023
SARS-CoV-2 infection as a model to study the effect of cinnamaldehyde as adjuvant therapy for viral pneumoniaBianca Vezzani, Mariasole Perrone, Marianna Carinci, et al.
Allergy|July 28, 2022
Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate-to-severe type 2 asthmaAlberto Papi, Jonathan Corren, Mario Castro, et al.
Respiratory Medicine|September 10, 2022
Dupilumab efficacy in subgroups of type 2 asthma with high-dose inhaled corticosteroids at baselineArnaud Bourdin, J Christian Virchow, Alberto Papi, et al.
The Journal of Allergy and Clinical Immunology. in Practice|December 26, 2022
Dupilumab Efficacy in Patients With Uncontrolled or Oral Corticosteroid-Dependent Allergic and Nonallergic AsthmaGuy Brusselle, Santiago Quirce, Alberto Papi, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|December 17, 2009
Oxidative/nitrosative stress selectively altered A(2B) adenosine receptors in chronic obstructive pulmonary diseaseKatia Varani, Gaetano Caramori, Fabrizio Vincenzi, et al.
American Journal of Respiratory and Critical Care Medicine|February 8, 2024
Biomarkers Associated with Lung Function Decline and Dupilumab Response in Patients with AsthmaIan D Pavord, Lucia De Prado Gómez, Guy Brusselle, et al.
Pageof 43